NASDAQ : AMRX

Amneal Pharmaceuticals, Inc.

$18.46 USD

-$0.02 (-0.11%)

Volume
1.76M
Average Volume
1.92M
Market Capitalization
$5.89B
P/E Ratio
37.11
Dividend Yield
0.00%
Price Target
$19.00
Year High
$19.26
Year Low
$7.98
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.20
Company Overview

NASDAQ

Chirag K. Patel

Drug Manufacturers - Specialty & Generic

Healthcare

AMRX

8500

US

USD

https://www.amneal.com

908 947 3120

03168L105

0001723128

Liquidity Metrics

84.54

2.20

1.44

0.14

0.00

Sales & Valuation

$3.02B

1.89

178.43

70.93

0.26

Profitability

$0.22

$72.06M

5.05%

6.45%

-326.75%

4.17%

P/E Metrics

37.11

0.01

0.01

Analyst Price Target & Rating

$19.00

$25.00

$16.00

Neutral

3/5

17 Analysts

-2.84%

Financial Health Scores

2.55

7/9

$1.06B

$3.78B

$3.66B

$457.91M

Key Metrics (TTM)

$8.57B

2.75

13.13

2.20

-326.75%

13.38%

2.67%

1.41%

$1.07

111 days

Company Executives
Name Title
Sanjay Kumar Jain Chief Quality Officer
Anthony DiMeo Head/VP of Investor Relations
Gregory Sgammato Senior Vice President of Corporate Development
Jason Daly Executive Vice President, Chief Legal Officer & Corporate Secretary
Pranav Mehta Senior Vice President of Strategic Sourcing & Supply Management
Nikita Shah Executive Vice President & Chief Human Resources Officer
Andrew S. Boyer Executive Vice President and Chief Commercial Officer of Generics & Biosciences
Chirag K. Patel Co-Founder, Co-CEO, President & Director
Anastasios G. Konidaris Executive Vice President & Chief Financial Officer
Chintu Patel Co-Founder, Co-CEO & Director
Poll Results

No votes yet today — be the first to share your view!

About Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectr ... um of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

Arkadios Wealth Advisors Takes Position in Amneal Pharmaceuticals, Inc. $AMRX

2026-08-01 03:57:28

Arkadios Wealth Advisors purchased a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 335,098 shares of the company's stock, valued at approximately $4,165,000. Arkadios Wealth Advisors owned approximately

AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised

2026-07-31 12:15:17

Amneal tops second-quarter earnings and revenue estimates and lifts its 2026 outlook.

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript

2026-07-30 14:23:46

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript

Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics

2026-07-30 10:31:23

Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amneal Pharmaceuticals Q2 Earnings Call Highlights

2026-07-30 10:06:18

Amneal Pharmaceuticals NASDAQ: AMRX reported second-quarter 2026 revenue of $796 million, up 10% from a year earlier, as growth in its affordable medicines and specialty businesses offset a decline at its AvKARE distribution unit. The company raised its full-year revenue, adjusted EBITDA and adjusted earnings-per-share outlook, citing broad-based demand, new product launches and favorable product mix.

Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimates

2026-07-30 08:20:50

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.25 per share a year ago.

Amneal Reports Second Quarter 2026 Financial Results

2026-07-30 06:00:00

–  Q2 2026 Net Revenue of $796 million ; GAAP Net Income of $58 million ; Diluted Income per Share of $0.18 – – Adjusted EBITDA of $206 million ; Adjusted Diluted EPS of $0.30 – – Raising 2026 Full Year Guidance – – Successful Debt Repricing in July Reduces Interest Cost –

Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm

2026-07-23 13:27:00

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company's current shareholders. The investigation seeks to determine whether Amneal or the company's officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions. Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional infor.

Frequently Asked Questions

What is the current Amneal Pharmaceuticals, Inc. (AMRX) stock price?

Amneal Pharmaceuticals, Inc.(NASDAQ:AMRX) stock price is $18.46 in the last trading session. During the trading session, AMRX stock reached the peak price of $19.26 while $7.98 was the lowest point it dropped to. The percentage change in AMRX stock occurred in the recent session was --0.11% while the dollar amount for the price change in AMRX stock was -$0.02.

AMRX's industry and sector of operation?

The NASDAQ listed AMRX is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of AMRX?

Sanjay Kumar Jain | Chief Quality Officer
Anthony DiMeo | Head/VP of Investor Relations
Gregory Sgammato | Senior Vice President of Corporate Development
Jason Daly | Executive Vice President, Chief Legal Officer & Corporate Secretary
Pranav Mehta | Senior Vice President of Strategic Sourcing & Supply Management

How many employees does AMRX have?

Number of AMRX employees currently stands at 8500. AMRX operates from 400 Crossing Boulevard, Bridgewater, NJ 08807, US.

Link for AMRX official website?

Official Website of AMRX is: https://www.amneal.com

How do I contact AMRX?

AMRX could be contacted at phone #908 947 3120 and can also be accessed through its website. AMRX operates from 400 Crossing Boulevard, Bridgewater, NJ 08807, US.

How many shares of AMRX are traded daily?

The average number of AMRX shares traded daily for last 3 months was 1.92M.

What is the market cap of AMRX currently?

The market value of AMRX currently stands at $5.89B with its latest stock price at $18.46